143 related articles for article (PubMed ID: 27616636)
1. Antiplatelet activity of flavonoid and coumarin drugs.
Zaragozá C; Monserrat J; Mantecón C; Villaescusa L; Zaragozá F; Álvarez-Mon M
Vascul Pharmacol; 2016 Dec; 87():139-149. PubMed ID: 27616636
[TBL] [Abstract][Full Text] [Related]
2. Binding and antiplatelet activity of quercetin, rutin, diosmetin, and diosmin flavonoids.
Zaragozá C; Monserrat J; Mantecón C; Villaescusa L; Álvarez-Mon MÁ; Zaragozá F; Álvarez-Mon M
Biomed Pharmacother; 2021 Sep; 141():111867. PubMed ID: 34229245
[TBL] [Abstract][Full Text] [Related]
3. Novel compounds of hybrid structure pyridazinone-coumarin as potent inhibitors of platelet aggregation.
Costas-Lago MC; Besada P; Cano E; Terán C
Future Med Chem; 2019 Aug; 11(16):2051-2062. PubMed ID: 31538518
[No Abstract] [Full Text] [Related]
4. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase.
Kang WS; Chung KH; Chung JH; Lee JY; Park JB; Zhang YH; Yoo HS; Yun YP
J Cardiovasc Pharmacol; 2001 Dec; 38(6):875-84. PubMed ID: 11707691
[TBL] [Abstract][Full Text] [Related]
5. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1.
Zaragozá C; Zaragozá F; Gayo-Abeleira I; Villaescusa L
Molecules; 2021 May; 26(10):. PubMed ID: 34069658
[TBL] [Abstract][Full Text] [Related]
7. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
8. Potential Mechanism of Platelet GPIIb/IIIa and Fibrinogen on Retinal Vein Occlusion.
Ren H; Sun Y; Li Y; Yuan X; Jiang B; Zhang W; Liu G; Lu P
Curr Eye Res; 2024 Jul; 49(7):731-741. PubMed ID: 38482878
[TBL] [Abstract][Full Text] [Related]
9. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
Huang TF; Chang CH; Ho PL; Chung CH
Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of 1,4-benzodioxine derivatives as novel platelet aggregation inhibitors.
Xie Z; Zhao L; Ding X; Kong Y; Li Z
Future Med Chem; 2018 Feb; 10(4):367-378. PubMed ID: 29380625
[TBL] [Abstract][Full Text] [Related]
11. Coumarin Derivatives Inhibit ADP-Induced Platelet Activation and Aggregation.
Lu PH; Liao TH; Chen YH; Hsu YL; Kuo CY; Chan CC; Wang LK; Chern CY; Tsai FM
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807298
[TBL] [Abstract][Full Text] [Related]
12. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
14. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Xiao Z; Théroux P; Frojmovic M
Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
[TBL] [Abstract][Full Text] [Related]
15. A novel anti-platelet peptide (Z4A5) potential for glycoprotein IIb/IIIa inhibits platelet aggregation.
Li YX; Sun Q; Zhang H; Ren ST; Liao YR; Wang Y; Shen XL; Wang B
Thromb Res; 2012 May; 129(5):e217-22. PubMed ID: 22445430
[TBL] [Abstract][Full Text] [Related]
16. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cytotoxic and anti-platelet activities of polyphenolic extracts from Arnica montana flowers and Juglans regia husks.
Rywaniak J; Luzak B; Podsedek A; Dudzinska D; Rozalski M; Watala C
Platelets; 2015; 26(2):168-76. PubMed ID: 24679412
[TBL] [Abstract][Full Text] [Related]
18. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins.
Di Braccio M; Grossi G; Roma G; Grazia Signorello M; Leoncini G
Eur J Med Chem; 2004 May; 39(5):397-409. PubMed ID: 15110966
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis of the platelet surface area and surface density of glycoprotein IIb-IIIa of unactivated human platelets of various sizes.
Leytin V; Shapiro H; Novikov I; Radnay J
Biochem Biophys Res Commun; 1996 Sep; 226(1):94-100. PubMed ID: 8806597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
